Determination of Type I Receptor Specificity by the Type II Receptors for TGF-beta or Activin

Overview

Journal Science

Specialty Science

Date 1993 Nov 5

PMID 8235612

Citations 48

Authors

R Ebner

R H Chen

S Lawler

T Zioncheck

R Derynck

Affiliations

Soon will be listed here.

Abstract

Transforming growth factor-beta (TGF-beta) and activin signal primarily through interaction with type I and type II receptors, which are transmembrane serine-threonine kinases. Tsk 7L is a type I receptor for TGF-beta and requires coexpression of the type II TGF-beta receptor for ligand binding. Tsk 7L also specifically bound activin, when coexpressed with the type IIA activin receptor. Tsk 7L could associate with either type II receptor and the ligand binding specificity of Tsk 7L was conferred by the type II receptor. Tsk 7L can therefore act as type I receptor for both activin and TGF-beta, and possibly other ligands.

Citing Articles

Smad transcription factors as mediators of 7 transmembrane G protein-coupled receptor signalling.

Chia Z, Kumarapperuma H, Zhang R, Little P, Kamato D Acta Pharmacol Sin. 2024; .

PMID: 39506064 DOI: 10.1038/s41401-024-01413-6.

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.

Srinivasan D, Arostegui M, Goebel E, Hart K, Aykul S, Lees-Shepard J Biomolecules. 2024; 14(1).

PMID: 38254701 PMC: 10813747. DOI: 10.3390/biom14010101.

The Fate of Leydig Cells in Men with Spermatogenic Failure.

Adamczewska D, Slowikowska-Hilczer J, Walczak-Jedrzejowska R Life (Basel). 2022; 12(4).

PMID: 35455061 PMC: 9028943. DOI: 10.3390/life12040570.

Immune Inhibitory Properties and Therapeutic Prospects of Transforming Growth Factor-Beta and Interleukin 10 in Autoimmune Hepatitis.

Czaja A Dig Dis Sci. 2021; 67(4):1163-1186.

PMID: 33835375 DOI: 10.1007/s10620-021-06968-6.

A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors.

Listik E, Horst B, Choi A, Lee N, Gyorffy B, Mythreye K PLoS One. 2021; 16(4):e0249558.

PMID: 33819300 PMC: 8021191. DOI: 10.1371/journal.pone.0249558.